By Steve Moore | Monday 16 May 2022
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Previously writing on group now describing itself as “a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments” Kromek (KMK), in July with the shares down towards 15p I reviewed “well-placed to capitalise on the substantial opportunities”, concluding still a sell. It today provides an update, with its year ended 30th April.